尤瑞克林对分水岭脑梗死患者NIHSS评分的影响

Impact of urinary kallidinogenase to NIHSS scores in patients with cerebral watershed infarcts

目的观察尤瑞克林对分水岭脑梗死的治疗效果。方法分水岭脑梗死患者60例,随机分为2组:尤瑞克林治疗组(30例)和对照组(30例)。2组均给予抗小板聚集、调脂、调控血压、改善微循环及保护脑细胞等治疗,治疗组在此基础上加用尤瑞克林0.15 PNA静滴。治疗前后应用美国国立卫生研究院卒中量表(NIHSS)进行神经功能缺损评定。结果 2组治疗后NIHSS评分均低于治疗前,且治疗后治疗组NIHSS评分明显低于对照组。治疗组疗效优于对照组。结论尤瑞克林治疗分水岭脑梗死安全有效。

Objective To observe the effect of urinary kallidinogenase in the treatment of cerebral watershed infarcts. Methods Sixty patients with cerebral infarction were randomly divided into uribe elindamycin treatment group （n -30） and control group （n = 30）. Two groups received anti-p[atelet aggregation, lipid, blood pressure regulation to improve microcirculation and protect brain cells. In addition to this basic treatment, the treatment group received uribe the Brooklyn 0. 15PNA infusion. Neurological deficit was assessed by using the NIH Stroke Scale （NIHSS） before and after treatment. Results After treatment, NIHSS score were lower than before treatment in both groups, and N1HSS score in the treatment group was significantly lower than that in the con- trol group. The efficacy in the treatment group was superior to the control group. Conclusion Uri- nary kallidinogenase in patients with cerebral watershed infarcts is safe and effective.